Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.

Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG Jr, Ohh M.

Mol Cell Biol. 2004 Apr;24(8):3251-61.

2.

Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.

Maynard MA, Ohh M.

Am J Nephrol. 2004 Jan-Feb;24(1):1-13. Epub 2003 Dec 3. Review.

3.

The von Hippel-Lindau tumor suppressor protein.

Ivan M, Kaelin WG Jr.

Curr Opin Genet Dev. 2001 Feb;11(1):27-34. Review.

PMID:
11163147
4.

The von Hippel-Lindau tumor suppressor gene.

Kondo K, Kaelin WG Jr.

Exp Cell Res. 2001 Mar 10;264(1):117-25. Review.

PMID:
11237528
5.

The von Hippel-Lindau tumor suppressor gene and kidney cancer.

Kaelin WG Jr.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S. Review.

6.
7.

Molecular targets from VHL studies into the oxygen-sensing pathway.

Maynard MA, Ohh M.

Curr Cancer Drug Targets. 2005 Aug;5(5):345-56. Review.

PMID:
16101382
8.

Role of VHL gene mutation in human cancer.

Kim WY, Kaelin WG.

J Clin Oncol. 2004 Dec 15;22(24):4991-5004. Review.

PMID:
15611513
9.

The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.

Sufan RI, Jewett MA, Ohh M.

Am J Physiol Renal Physiol. 2004 Jul;287(1):F1-6. Review.

PMID:
15180922
10.

The von Hippel-Lindau tumour suppressor protein: new perspectives.

Ohh M, Kaelin WG Jr.

Mol Med Today. 1999 Jun;5(6):257-63. Review.

PMID:
10366821
11.

Von Hippel-Lindau disease: clinical and molecular perspectives.

Clifford SC, Maher ER.

Adv Cancer Res. 2001;82:85-105. Review.

PMID:
11447766
12.

The VHL tumor suppressor and HIF: insights from genetic studies in mice.

Kapitsinou PP, Haase VH.

Cell Death Differ. 2008 Apr;15(4):650-9. doi: 10.1038/sj.cdd.4402313. Epub 2008 Jan 25. Review.

13.
14.

The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.

Barry RE, Krek W.

Trends Mol Med. 2004 Sep;10(9):466-72. Review. No abstract available.

PMID:
15350900
15.

Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.

Nyhan MJ, O'Sullivan GC, McKenna SL.

Biochem Soc Trans. 2008 Jun;36(Pt 3):472-8. doi: 10.1042/BST0360472. Review.

PMID:
18481984
16.

The HIF pathway: implications for patterns of gene expression in cancer.

Wykoff CC, Pugh CW, Harris AL, Maxwell PH, Ratcliffe PJ.

Novartis Found Symp. 2001;240:212-25; discussion 225-31. Review.

PMID:
11727931
17.

von Hippel-Lindau tumor suppressor: not only HIF's executioner.

Czyzyk-Krzeska MF, Meller J.

Trends Mol Med. 2004 Apr;10(4):146-9. Review.

PMID:
15162797
18.

Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.

Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ.

IUBMB Life. 2001 Jul;52(1-2):43-7. Review.

19.

Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL.

Li M, Kim WY.

J Cell Mol Med. 2011 Feb;15(2):187-95. doi: 10.1111/j.1582-4934.2010.01238.x. Review.

20.

[Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].

Moch H.

Pathologe. 2008 Nov;29 Suppl 2:149-52. doi: 10.1007/s00292-008-1034-y. Review. German.

PMID:
18751708

Supplemental Content

Support Center